Gene interaction analysis also highlighted CrkL as a critical gene in the survival and spread of CML, indicating its significance in Imatinib-resistant CML beyond its current usage as only a predictor of clinical outcome and as a potential druggable target. The gene discussed is CRKL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.